Avner Dor, B. Pharm, M.Sc. Pharmaceutical Medicine

CEO, Founder

Avner joined the pharmaceutical industry in Regulatory Affairs as a Qualified Person for Luxembourg Pharmaceuticals in 1997. He served as Regulatory Affairs Manager with Trima Israel, one of the leading generic manufacturers in Israel, followed by 6 years with Pfizer Israel as Regulatory Affairs Manager, Head of Pharmacovigilance and Quality Assurance, and as Director of Clinical Operations before establishing Dor Pharmaceutical Services in 2011.

Avner is well-respected in the Israeli Regulatory Affairs and Clinical Trials communities by regulators and colleagues. He has earned a reputation for integrity and efficient, effective support throughout full project lifecycles and beyond.

Avner is certified as a Registered Pharmacist, Israeli Regulatory Affairs Manager and Israeli Qualified Person. He is also a member of the Pharmaceutical society of Israel and the Israeli PDA (Parenteral Drug Association). He is an Israeli QPPV (Qualified Person for Pharmacovigilance) for global pharmaceutical companies.

Rami Mittelman, M.Sc. Computer Science


Rami hRami Mittelman - COOas 30 years of leadership experience in Hi-Tech companies. He started in R&D positions in Scite x (one of the Israeli Hi-Tech flagships) and Cubital (one of the inventors of the 3D printing). In 1995 Rami joined Verint (a global leader of Actionable Intelligence solutions) and served as a Senior VP of Product Marketing and business unit Managing Director. In 2008 he served as the COO and GM Israel of Payoneer (a provider of innovative payment solutions). Rami joined Dor Pharmaceutical Services in 2012.

Rami have diverse experience both in start-ups and large international companies. He is highly experienced in strategic planning, in building and managing processes and in particular in quality management.

Liat Hochman, M.Sc. Microbiology

VP Clinical Trials

Liat joined the pharmaceutical industry as a CRA in 1996, and has held key Clinical Research Organization (CRO) positions. She established and headed the Israeli office of Hesperion CH for 9 years, being responsible for clinical operations and administration. During the last 3 years she served as Regional Director with Averion International Israel Ltd.

Liat is well recognized in the Israeli clinical operations arena for successful performance and delivery of high quality project deliverables, on time and within budget.

In addition – she is well known for her ability to resource client projects with trained professionals and to retain and develop these professionals within the company, Liat has vast experience in managing both local and international trials.

Liat joined Dor Pharmaceutical Services in 2011.

Sara Horn, PhD

VP of International Regulatory Affairs

Sara Horn is a sought-after global regulatory affairs expert recognized for achieving unprecedented approvals for a broad array of pharmaceuticals (including combination drugs) and biologics (including progressive immunotherapies). In her multi-decade career, Sara has worked for a large spectrum of international pharmaceutical companies, both as an internal executive and an external consultant. In each initiative that Sara undertakes, she maintains a targeted focus on the mission to introduce safe treatments to patients in need.

Dr. Horn has a well-earned reputation for success across the complete product lifecycle – from development to clinical trials and marketing authorization through maintenance. Her creative problem solving has assisted companies in surmounting barriers and accelerating product approval from the USA FDA, the EU FMA, EU member states and the Israeli Ministry of Health.

In addition to her role with Dor, Sara manages a regulatory consulting firm, where she spearheads a variety drug development projects for medications, small molecules, biologics and combination products.

Prior her experience as a consultant, Sara served as Vice President of Clinical and Regulatory Affairs for Omrix Bio-Pharmaceuticals, a subsidiary of Johnson and Johnson, where she directed the clinical and regulatory strategies of a variety of biological and combination projects. 

Sara held the position of Vice President of Product Development at Vascular Biogenics, which innovated gene therapy and small molecule products. Prior to this, Sara was the Regulatory Affairs Manager for Perio Products, a super-generic developer and worked as a Regulatory Affairs Associate for Interpharm, an Ares Serono biotechnology company.  

Sharing her in-depth knowledge with the pharma industry, Dr. Horn teaches regulatory affairs and lectures in forums related to drugs, biologics and combination products.


Sara completed her PhD and post-doctoral fellowship in biochemistry and immunology.

Erica Kofler-Leder, BSc in Chemistry

VP, Validation Services and Business Development

Erica is a career life-science professional specializing in quality assurance and regulatory compliance for drugs and medical devices. With expertise in cGMP, GDP and GLP, Erica has a proven skill range in both high-level leadership and hands-on knowledge, covering the entire value chain. She consistently and successfully streamlines processes, shortens their time to completion and identifies resource savings, while achieving excellence in compliance.

Erica has worked for companies such as Teva and Medison, serving as Division Manager for Consulting and Quality Services, Quality Assurance Manager and QA Section Manager. She is certified as a Senior Auditor.

Erica’s deliverables have been benchmarks in the industry serving as the foundation of the Israeli Ministry of Health standard operating procedures. As a natural educator and mentor with a distinct customer-focused style, Erica has a personal mission to share her knowledge and promote customer self-reliance.